Acute kidney injury
Conditions
Brief summary
The primary endpoint of the trial is the time to MACE (major adverse cardiovascular events), i.e. a composite outcome composed of all-cause mortality and all unscheduled hospital readmission for cardiovascular events (acute heart failure, stroke, acute coronary syndrome) during the year following ICU or TCU discharge
Detailed description
Albuminuria >0.3 g/day one year after ICU or TCU discharge, Occurrence of chronic kidney disease one year after ICU or TCU discharge defined as eGFR <60 ml/min/1.73m2, Decrease of estimated glomerular filtration from baseline to one year after enrollment, Change in Chronic kidney disease staging one year after enrollment, New episode of acute kidney injury (according to the KDIGO criteria) requiring hospitalization, Hyperkalemia >6 mmol/L, Death, Biological collection built up at inclusion and at the end of the study
Interventions
DRUGPlacebo IRBESARTAN EG 150 mg
DRUGIrbesartan EG 150 mg comprimés pelliculés
Sponsors
Assistance Publique Hopitaux De Paris
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint of the trial is the time to MACE (major adverse cardiovascular events), i.e. a composite outcome composed of all-cause mortality and all unscheduled hospital readmission for cardiovascular events (acute heart failure, stroke, acute coronary syndrome) during the year following ICU or TCU discharge | — |
Secondary
| Measure | Time frame |
|---|---|
| Albuminuria >0.3 g/day one year after ICU or TCU discharge, Occurrence of chronic kidney disease one year after ICU or TCU discharge defined as eGFR <60 ml/min/1.73m2, Decrease of estimated glomerular filtration from baseline to one year after enrollment, Change in Chronic kidney disease staging one year after enrollment, New episode of acute kidney injury (according to the KDIGO criteria) requiring hospitalization, Hyperkalemia >6 mmol/L, Death, Biological collection built up at inclusion and at the end of the study | — |
Countries
France
Outcome results
None listed